Astrana Health Inc reported second-quarter 2026 revenue of $973 million, up 49% year-over-year, and raised its full-year adjusted EBITDA guidance to a range of $255 million to $280 million. Adjusted diluted earnings per share reached a record $0.80, a 45% increase, while adjusted EBITDA rose 43% to $69 million. The company also reaffirmed its full-year revenue guidance of $3.8 billion to $4.1 billion and free cash flow guidance of $105 million to $132.5 million. Net leverage declined to 2.26 times on a trailing 12-month basis, and the company retired $92 million of debt during the quarter. Astrana Health cited broad-based outperformance and continued maturation of full-risk cohorts as drivers for the raised outlook.
Astrana Health IncRecord Q2 earnings and raised full-year adjusted EBITDA guidance
